-+ 0.00%
-+ 0.00%
-+ 0.00%

Fujian Huakang, a subsidiary of Chengyi Pharmaceutical (603811.SH), obtained drug GMP compliance test results

Zhitongcaijing·09/28/2026 07:49:07
Listen to the news

Zhitong Finance App News, Chengyi Pharmaceutical (603811.SH) issued an announcement. Recently, the company's subsidiary Fujian Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as “Fujian Huakang”) obtained the drug's GMP compliance test results (number: FJSC2026-038) from the Fujian Drug Administration website. The production and quality management of the company's API glucosamine hydrochloride (added a production line for glucosamine hydrochloride in the B09 workshop) complies with the requirements of the “Pharmaceutical Production Quality Management Code (2010 Revision)” and its appendix.

This time, Fujian Huakang obtained the GMP compliance test results for the above drugs, indicating that Fujian Huakang's related production lines meet GMP requirements, which helps Fujian Huakang to continue to guarantee product quality and stable production capacity, better meet market demand, and have a positive effect on the company's future development.